Polycystic Ovarian Syndrome: Diagnosis and Workup
Updated
Polycystic ovarian syndrome is diagnosed clinically, not with one test. Under the 2023 International Evidence-based Guideline, an adult needs two of three features: irregular cycles, clinical or biochemical hyperandrogenism, and polycystic ovarian morphology on ultrasound or a raised anti-Müllerian hormone (AMH) level, once conditions that look the same have been excluded. Adolescents need both irregular cycles and hyperandrogenism, without ultrasound or AMH. The core blood tests are total and unbound testosterone, thyroid-stimulating hormone (TSH), prolactin, 17-hydroxyprogesterone and follicle-stimulating hormone (FSH), and a confirmed diagnosis starts a second round of checks for glucose, lipids, blood pressure, mood, sleep apnoea and endometrial risk. This guide walks through that workup in order.
- Adults2 of 3: irregular cycles, hyperandrogenism, ultrasound or AMH
- AdolescentsBoth irregular cycles and hyperandrogenism; no ultrasound or AMH
- Exclude firstTSH, prolactin, 17-OHP and FSH; others if the picture fits
- After diagnosisGlucose, lipids, blood pressure, mood, sleep apnoea, endometrium
The workup has more decision points than the two-of-three rule suggests: which androgen assay to trust, whether the patient is on the pill, when AMH can stand in for a scan, and which mimics need a test rather than a history. AskMed is an app for doctors, nurses, pharmacists, medical students and researchers that answers medical questions from clinical guidelines and studies and links every claim to its source. On a PCOS workup, that means the answer quotes the guideline recommendation behind it, so you can check the wording yourself.
Ask AskMed which tests the 2023 guideline algorithm uses to exclude other causes before a PCOS diagnosis:
What are the Rotterdam criteria for polycystic ovarian syndrome?
The Rotterdam criteria come from a 2003 consensus workshop sponsored by ESHRE and ASRM, which concluded that PCOS is a syndrome of ovarian dysfunction with two other cardinal features, hyperandrogenism and polycystic ovary morphology, and that no single criterion is enough for a diagnosis. The 2023 International Evidence-based Guideline, led by Teede and colleagues with 39 professional and consumer organisations covering 71 countries, keeps that two-of-three structure, with other causes excluded first. Its main change is that a raised serum AMH can now replace ultrasound for the ovarian criterion in adults. It also simplifies the path: when irregular cycles and hyperandrogenism are both present, neither an ultrasound nor an AMH test is needed. The guideline treats the diagnosis as enduring and lifelong, and after menopause it can be made from a past diagnosis or a long history of oligo-amenorrhoea with hyperandrogenism or polycystic ovaries during the reproductive years, roughly ages 20 to 40.
The cycle part of the criteria is defined by the time since menarche, from cycles shorter than 21 or longer than 45 days in years 1 to 3 to shorter than 21 or longer than 35 days afterwards; the full list, with symptoms, risks and treatment, is in our overview of polycystic ovary syndrome. Two points matter most in a workup. Ovulatory dysfunction can occur with regular cycles, and the guideline says a serum progesterone can be measured if anovulation needs to be confirmed. And the criteria apply to the condition that a 2026 consensus in The Lancet renamed polyendocrine metabolic ovarian syndrome (PMOS); the consensus describes a transition period, and the 2023 guideline's criteria are the ones described here.
- History and examination: cycle pattern since menarche, hirsutism on the modified Ferriman-Gallwey score, acne, scalp hair loss, speed of onset.
- Exclude mimics: TSH, prolactin, 17-OHP and FSH; pregnancy, Cushing's syndrome or a tumour when the picture fits.
- Apply the criteria: irregular cycles plus hyperandrogenism is enough; otherwise ultrasound or AMH in adults.
- Screen after diagnosis: glycaemic status, lipids, blood pressure, depression and anxiety, sleep apnoea symptoms, endometrial risk.
Which blood tests confirm hyperandrogenism?
Biochemical hyperandrogenism is confirmed with total testosterone and the unbound fraction, the 2023 guideline says, and the unbound fraction can be estimated by a calculated androgen index that uses sex hormone-binding globulin (SHBG). If neither is raised, androstenedione and dehydroepiandrosterone sulfate (DHEAS) could be measured, although both are less specific and DHEAS falls with age. The assay matters as much as the analyte: laboratories should use validated liquid chromatography-tandem mass spectrometry (LC-MS/MS), because direct immunoassays have limited accuracy and poor sensitivity and precision for diagnosing hyperandrogenism in PCOS. The unbound fraction should be calculated or measured by equilibrium dialysis or ammonium sulfate precipitation. Blood tests add the most when clinical signs are minimal or absent; hirsutism on its own should be considered predictive of biochemical hyperandrogenism in adults, while acne or female pattern hair loss without hirsutism are weak predictors. Repeating androgen levels to follow PCOS in adults has a limited role.
- On the combined pill: androgens cannot be assessed reliably, because the pill raises SHBG and lowers gonadotrophin-driven androgen production. If testing is essential, the guideline says to stop the pill for at least 3 months and use other contraception meanwhile.
- Reference ranges: they vary widely between methods and laboratories and are often drawn from populations that include women with PCOS, so a value near the upper limit needs the clinical context.
- Hirsutism scoring: a modified Ferriman-Gallwey score of 4 to 6 or more, depending on ethnicity, with a photographic atlas; cosmetic self-treatment is common and can hide the signs.
- Very high or fast-rising androgens: consider ovarian or adrenal tumours, congenital adrenal hyperplasia, Cushing's syndrome, ovarian hyperthecosis after menopause, medicines and severe insulin resistance syndromes. Some androgen-secreting tumours raise levels only mildly, so a rapid onset matters more than the number.
When can AMH replace the ultrasound?
Serum AMH can replace the ovarian ultrasound only in adults, and only for the third criterion, polycystic ovarian morphology. The 2023 guideline states that AMH should not be used as a single test for PCOS, that it should not yet be used in adolescents, and that ultrasound and AMH should not both be done for the same criterion, to limit over-diagnosis. It also reminds clinicians that, in a patient with irregular cycles and hyperandrogenism, an AMH level is not needed at all. Interpretation depends on context: in the general population serum AMH peaks between ages 20 and 25, it is lower at a higher body mass index, it can be suppressed by current or recent combined pill use or ovarian surgery, and it varies across the menstrual cycle. No single international cut-off is given; laboratories should use population- and assay-specific thresholds. The guideline notes that AMH is a low-cost, convenient option for women without evidence of over-diagnosis.
When ultrasound is used, the adult threshold is a follicle number per ovary of 20 or more in at least one ovary. An ovarian volume of 10 mL or more, or 10 or more follicles in a single cross-section, can be used when older equipment or image quality does not allow a full follicle count, and transabdominal scans should mainly report volume or follicles per section. The transvaginal route is the most accurate if acceptable to the patient. The guideline asks for a standard report: last menstrual period or cycle stage, transducer frequency, route, the total number of 2 to 9 mm follicles per ovary, three measurements or volume of each ovary, dominant follicles of 10 mm or more (left out of the volume), and the endometrial thickness and pattern.
How is PCOS diagnosed in adolescents?
In adolescents, PCOS is diagnosed only when both ovulatory dysfunction and hyperandrogenism are present, because the 2023 guideline does not recommend ultrasound or AMH at this age: there are no definitive criteria for polycystic ovarian morphology in adolescents, and both tests have poor specificity. Cycle irregularity is judged against time since menarche, since irregular cycles are normal in the first year as part of the pubertal transition, and the guideline notes that mean age at menarche differs between populations. Clinical hyperandrogenism in this group means severe acne and hirsutism, and androgen levels in most adolescents reach adult ranges at 12 to 15 years of age. The value and timing of assessment should be discussed with the adolescent and their parents or guardians, taking account of psychosocial and cultural factors. Once the diagnosis is made, the guideline's screening for glycaemic status and depression applies to adolescents as well as adults.
Many adolescents show some features without meeting both criteria. For them, the guideline suggests describing an "increased risk" of PCOS and reassessing at or before full reproductive maturity, 8 years after menarche. That group includes adolescents who had PCOS features before starting the combined pill, those whose features persist and those with significant weight gain in adolescence. Because the combined pill makes androgen testing unreliable, documenting cycle pattern and hirsutism before it is started keeps a later assessment possible.
Which conditions must be ruled out before diagnosing PCOS?
Exclusion of other causes is part of the PCOS definition, and the 2023 guideline's diagnostic algorithm lists it as TSH, prolactin, 17-hydroxyprogesterone (17-OHP) and FSH, or other causes such as Cushing's syndrome and adrenal tumours when clinically indicated. The 2013 Endocrine Society guideline gives the reasoning: these mimics are comparatively easy to exclude, so all women should be screened with TSH, prolactin and 17-OHP. Thyroid disease can cause irregular cycles; a TSH above the upper limit suggests hypothyroidism and a suppressed TSH suggests hyperthyroidism. Hyperprolactinaemia can present with amenorrhoea or hirsutism, flagged by a prolactin above the assay's upper limit. Non-classic congenital adrenal hyperplasia, a milder form of inherited 21-hydroxylase deficiency, is found in 1.5% to 6.8% of patients presenting with androgen excess. FSH helps separate primary ovarian insufficiency, where FSH is high, from hypogonadotrophic hypogonadism, usually due to low body fat or intensive exercise, where FSH and LH are low or low-normal.
- Non-classic CAH: an early-morning (before 8 am) 17-OHP in the early follicular phase, ideally by LC-MS/MS, since levels rise with ovulation and random samples can be normal. The 2013 table gives a screening threshold of 200 to 400 ng/dL depending on the assay; borderline values need an ACTH (cosyntropin) stimulation test.
- Pregnancy: a serum or urine hCG when amenorrhoea, rather than infrequent periods, is the presentation.
- Hypothalamic amenorrhoea: low weight or heavy exercise, no signs of androgen excess, low LH, FSH and estradiol; multifollicular ovaries can appear and confuse the scan.
- Primary ovarian insufficiency: amenorrhoea with hot flushes or urogenital symptoms, high FSH and low estradiol.
- Androgen-secreting tumour: virilisation such as voice change, clitoromegaly or male pattern hair loss, with rapid onset; markedly raised testosterone or DHEAS, then ovarian ultrasound and adrenal imaging.
- Cushing's syndrome and acromegaly: test when discriminating signs are present, such as proximal myopathy, plethora, violaceous striae and easy bruising, or headaches, visual field loss and enlarging hands and feet.
The hard cases sit in the grey zones: a 17-OHP just above the screening threshold, a mildly raised testosterone with recent-onset hirsutism, or a prolactin just above the assay's upper limit. Ask AskMed how to interpret a borderline early-morning 17-OHP in a woman with hirsutism and irregular cycles, and the answer cites the Endocrine Society tables and the CAH guideline it draws on.
Check how the guidelines handle a borderline 17-OHP or prolactin result in AskMed:
Which metabolic tests follow a PCOS diagnosis?
Metabolic screening starts at the moment of diagnosis, because the 2023 guideline states that women with PCOS have a higher risk of impaired fasting glucose, impaired glucose tolerance and type 2 diabetes regardless of age and body mass index. Glycaemic status should be assessed at diagnosis in all adults and adolescents with PCOS and reassessed every 1 to 3 years, depending on other diabetes risk factors. The oral glucose tolerance test (OGTT) is recommended as the most accurate test regardless of BMI; if an OGTT cannot be done, fasting plasma glucose or HbA1c could be used, with significantly reduced accuracy. An OGTT should be considered before pregnancy or fertility treatment, could be offered at the first prenatal visit if not done earlier, and should be offered to all women with PCOS at 24 to 28 weeks of pregnancy. Insulin assays are of limited clinical relevance and are not recommended in routine care, even though insulin resistance is part of the pathophysiology.
- Lipids: a full profile (cholesterol, LDL, HDL and triglycerides) at diagnosis for everyone, whatever the age or BMI; repeat testing is then guided by the result and overall cardiovascular risk.
- Blood pressure: every year, and when planning a pregnancy or seeking fertility treatment, given the high risk of hypertensive disorders in pregnancy.
- Weight: asking permission before discussing or measuring weight, explaining how the number will be used, with awareness of weight stigma.
- Diabetes clinics: women with type 1 or type 2 diabetes have a higher risk of PCOS, and screening for it should be considered.
Which mood, sleep and endometrial checks are recommended?
Beyond glucose and lipids, the 2023 guideline asks clinicians to screen every adult and adolescent with PCOS for depression and every adult for anxiety, using regionally validated tools, and to assess, refer or treat when moderate or severe symptoms are found. The best screening interval is not known; a pragmatic approach is screening at diagnosis and repeating it according to clinical judgement, risk factors and life events, including the perinatal period, and screening covers the risk of self-harm and suicidal intent. Eating disorders and disordered eating should be considered at any weight, especially during weight management, with a full diagnostic interview by a qualified practitioner if suspected. Permission should be sought before discussing psychosexual function. For sleep, women should be asked about obstructive sleep apnoea symptoms, meaning snoring together with waking unrefreshed, daytime sleepiness or fatigue; a questionnaire such as the Berlin questionnaire can help, but diagnosis needs a formal sleep study. Features of PCOS can also harm body image.
Where the local depression and anxiety tools are the PHQ-9 and GAD-7, the PHQ-9 calculator and GAD-7 calculator score them and show the severity bands. The endometrium is handled differently: premenopausal women with PCOS have a markedly higher risk of endometrial hyperplasia and cancer, but the overall chance remains low, so routine screening is not recommended. The guideline lists long-standing untreated amenorrhoea, higher weight, type 2 diabetes and persistent thickened endometrium as added risk factors, and when excessive endometrial thickness is found, a biopsy with histology and a withdrawal bleed should be considered.
Putting these into a follow-up plan raises practical questions: how often to repeat the OGTT when a parent has type 2 diabetes, which validated mood tool fits a teenager, or when a thick endometrium on a PCOS scan needs sampling. Ask AskMed how often the 2023 guideline says to reassess glycaemic status in PCOS with additional diabetes risk factors, and each line of the answer links to the recommendation it comes from.
Build a guideline-based PCOS follow-up plan with AskMed:
When does a suspected PCOS case need urgent review?
Most people with suspected PCOS can be assessed in routine care, but some features point away from PCOS and toward conditions that need faster investigation. The 2023 guideline says new-onset, severe or worsening hyperandrogenism, including hirsutism, needs investigation for androgen-secreting tumours and ovarian hyperthecosis, and the Endocrine Society lists virilisation, such as a deepening voice, clitoromegaly or male pattern hair loss, with rapid onset as the pattern that suggests a tumour. After menopause, new or worsening hyperandrogenism should prompt the same search. Signs with high discriminating value for Cushing's syndrome, such as proximal muscle weakness, plethora, violaceous striae and easy bruising, call for screening, as do headaches, visual field loss and enlarging hands, feet or jaw for acromegaly. Amenorrhoea with hot flushes suggests primary ovarian insufficiency rather than PCOS. A mood screen that reveals thoughts of self-harm or suicide needs urgent assessment, and heavy bleeding with dizziness or fainting needs urgent care.
For anyone reading as a patient: see a doctor if your periods are irregular or have stopped, or if excess hair, acne or scalp hair loss is new or worsening. Seek urgent care for very heavy bleeding with dizziness or fainting, severe pelvic pain, or thoughts of harming yourself.
Frequently asked questions
Can PCOS be diagnosed while taking the combined pill?
Only partly. The pill raises SHBG and lowers androgen production, so blood androgen levels can't be read reliably. The 2023 guideline says that if biochemical testing is essential, the pill should be stopped for at least 3 months with other contraception in the meantime. Pre-pill cycle history and hirsutism scoring still count.
What AMH level means PCOS?
There is no single international cut-off. The 2023 guideline asks laboratories to use population- and assay-specific thresholds, and AMH changes with age, body mass index, recent pill use, ovarian surgery and cycle day. AMH can only stand in for the ultrasound criterion in adults; it is never a diagnosis on its own.
Is the LH to FSH ratio part of the diagnosis?
No. The Rotterdam criteria and the 2023 guideline use cycles, androgens and ovarian morphology, not LH. The 2003 consensus noted that raised LH is common in PCOS, but it is not required. In the workup, FSH and LH are mainly used to exclude primary ovarian insufficiency and hypothalamic amenorrhoea.
Should fasting insulin or HOMA-IR be checked in PCOS?
Not routinely. The 2023 guideline says insulin resistance is part of the pathophysiology but that clinically available insulin assays are of limited relevance and should not be used in routine care. Glycaemic status is assessed with an oral glucose tolerance test, or fasting glucose or HbA1c when that isn't possible.
Can PCOS be diagnosed after menopause?
Yes, retrospectively. The guideline says a diagnosis could be considered after menopause if there is a past diagnosis, or a long history of irregular cycles with hyperandrogenism or polycystic ovaries between about ages 20 and 40. New or worsening hyperandrogenism after menopause needs investigation for a tumour or ovarian hyperthecosis first.
Sources
- Teede HJ, Tay CT, Laven JJE, et al.; International PCOS Network. Recommendations From the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2023;108(10):2447-2469.
- Legro RS, Arslanian SA, Ehrmann DA, et al.; Endocrine Society. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2013;98(12):4565-4592.
- Speiser PW, Arlt W, Auchus RJ, et al. Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(11):4043-4088.
- Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19(1):41-47.
- Teede HJ, Khomami MB, Morman R, et al.; Global Name Change Consortium. Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process. Lancet. 2026;407(10545):2329-2339.
